Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Mayo Clinic
Mayo Clinic
Ohio State University
Duke University
OHSU Knight Cancer Institute
Wake Forest University Health Sciences
University of Oklahoma
Alliance for Clinical Trials in Oncology
University of California, Davis
City of Hope Medical Center
NRG Oncology
University of California, San Diego
City of Hope Medical Center
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Ohio State University Comprehensive Cancer Center
University of Pittsburgh
University of Pittsburgh
Jonsson Comprehensive Cancer Center
NuCana plc
Oslo University Hospital
NRG Oncology
Shanghai Junshi Bioscience Co., Ltd.
Thomas Jefferson University
University of California, Davis
Fondazione IRCCS Policlinico San Matteo di Pavia
Stanford University
Emory University
Stanford University
University Hospital, Antwerp
Dana-Farber Cancer Institute
Mayo Clinic
Yale University
University of Southern California
Beijing Friendship Hospital
Peking University Third Hospital
University of Florida
Rutgers, The State University of New Jersey
M.D. Anderson Cancer Center
Massachusetts General Hospital
Centre Georges Francois Leclerc
University of Florida
Western Sydney Local Health District
H. Lee Moffitt Cancer Center and Research Institute
The Christie NHS Foundation Trust
Jules Bordet Institute
Institut Bergonié
Scripps Health